{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:32:06Z","timestamp":1787509926373,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","issue":"37","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T00:00:00Z","timestamp":1501027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.vaccine.2017.07.086","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T19:30:14Z","timestamp":1501615814000},"page":"4942-4951","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes"],"prefix":"10.1016","volume":"35","author":[{"given":"Kirill","family":"Kalnin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudha","family":"Chivukula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Tibbitts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Stegalkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Cieszynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Sabharwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen F.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhashini","family":"Jagu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.S.","family":"Roden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Kleanthous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.07.086_b0005","article-title":"Progress and prospects for L2-based human papillomavirus vaccines","volume":"1\u201310","author":"Jiang","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.07.086_b0010","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1006\/viro.2000.0272","article-title":"Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes","volume":"270","author":"Roden","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.07.086_b0015","doi-asserted-by":"crossref","first-page":"6188","DOI":"10.1128\/JVI.73.7.6188-6190.1999","article-title":"Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6","volume":"73","author":"Kawana","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.07.086_b0020","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.virol.2010.10.017","article-title":"The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies","volume":"409","author":"Rubio","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.07.086_b0025","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/jnci\/djp106","article-title":"Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines","volume":"101","author":"Jagu","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2017.07.086_b0030","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1128\/JVI.03218-12","article-title":"Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine","volume":"87","author":"Jagu","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.07.086_b0035","doi-asserted-by":"crossref","first-page":"e55538","DOI":"10.1371\/journal.pone.0055538","article-title":"Optimization of multimeric human papillomavirus L2 vaccines","volume":"8","author":"Jagu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.07.086_b0040","doi-asserted-by":"crossref","first-page":"e97232","DOI":"10.1371\/journal.pone.0097232","article-title":"Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types","volume":"9","author":"Kwak","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.07.086_b0045","doi-asserted-by":"crossref","first-page":"12180","DOI":"10.1073\/pnas.89.24.12180","article-title":"Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic","volume":"89","author":"Kirnbauer","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.07.086_b0050","doi-asserted-by":"crossref","first-page":"6929","DOI":"10.1128\/JVI.67.12.6929-6936.1993","article-title":"Efficient self-assembly of human papillomavirus type 16 L1 and L1\u2013L2 into virus-like particles","volume":"67","author":"Kirnbauer","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.07.086_b0055","doi-asserted-by":"crossref","first-page":"4729","DOI":"10.1038\/srep04729","article-title":"A high-performance thioredoxin-based scaffold for peptide immunogen construction: proof-of-concept testing with a human papillomavirus epitope","volume":"4","author":"Canali","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2017.07.086_b0060","doi-asserted-by":"crossref","first-page":"e49751","DOI":"10.1371\/journal.pone.0049751","article-title":"VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus","volume":"7","author":"Tumban","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.07.086_b0065","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1038\/jid.2013.253","article-title":"Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses","volume":"133","author":"Schellenbacher","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.vaccine.2017.07.086_b0070","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.1016\/j.vaccine.2015.09.005","article-title":"Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17\u201336 epitopes","volume":"33","author":"Jagu","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.07.086_b0075","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1006\/viro.1995.1392","article-title":"Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4","volume":"211","author":"Chandrachud","year":"1995","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.07.086_b0080","doi-asserted-by":"crossref","first-page":"13927","DOI":"10.1128\/JVI.00936-07","article-title":"Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N-terminus of HPV16 minor capsid antigen L2","volume":"81","author":"Gambhira","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.07.086_b0085","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.1073\/pnas.0800868105","article-title":"Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2","volume":"105","author":"Alphs","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.07.086_b0090","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1016\/j.vaccine.2014.04.032","article-title":"Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes","volume":"32","author":"Kalnin","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.07.086_b0095","doi-asserted-by":"crossref","first-page":"13927","DOI":"10.1128\/JVI.00936-07","article-title":"A protective and broadly cross-neutralizing epitope of Human Papillomavirus L2","volume":"81","author":"Gambhira","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.07.086_b0100","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01583-06","article-title":"Preclinical model to test HPV capsid vaccines in vivo using infectious HPV\/CRPV chimeric papillomavirus particles","author":"Mejia","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.07.086_b0105","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.virol.2003.12.027","article-title":"Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18","volume":"321","author":"Pastrana","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.07.086_b0110","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1016\/j.vaccine.2010.04.039","article-title":"Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection","volume":"28","author":"Jagu","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.07.086_b0115","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1128\/JVI.69.6.3959-3963.1995","article-title":"Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection","volume":"69","author":"Breitburd","year":"1995","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.07.086_b0120","doi-asserted-by":"crossref","first-page":"13253","DOI":"10.1128\/JVI.06093-11","article-title":"A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection","volume":"85","author":"Longet","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.07.086_b0125","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.virol.2012.09.006","article-title":"Monoclonal antibodies recognizing cross-neutralization epitopes in human papillomavirus 16 minor capsid protein L2","volume":"434","author":"Nakao","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.07.086_b0130","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/35074106","article-title":"The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5","volume":"410","author":"Hayashi","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2017.07.086_b0135","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.vaccine.2006.08.013","article-title":"Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity","volume":"25","author":"Huleatt","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.07.086_b0140","doi-asserted-by":"crossref","first-page":"ofw015","DOI":"10.1093\/ofid\/ofw015","article-title":"Phase 1 Safety and Immunogenicity Study of a Quadrivalent Seasonal Flu Vaccine Comprising Recombinant Hemagglutinin-Flagellin Fusion Proteins","volume":"3","author":"Tussey","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.086_b0145","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.virol.2005.04.011","article-title":"Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2","volume":"337","author":"Pastrana","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.07.086_b0150","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1053\/j.seminoncol.2014.12.032","article-title":"Human papillomaviruses and non-melanoma skin cancer","volume":"42","author":"McLaughlin-Drubin","year":"2015","journal-title":"Semin Oncol"},{"key":"10.1016\/j.vaccine.2017.07.086_b0155","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4161\/21645515.2014.983858","article-title":"HPV vaccination for prevention of skin cancer","volume":"11","author":"Vinzon","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.07.086_b0160","doi-asserted-by":"crossref","first-page":"e1003924","DOI":"10.1371\/journal.ppat.1003924","article-title":"Protective vaccination against papillomavirus-induced skin tumors under immunocompetent and immunosuppressive conditions: a preclinical study using a natural outbred animal model","volume":"10","author":"Vinzon","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2017.07.086_b0165","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1473-3099(12)70187-1","article-title":"Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis","volume":"12","author":"Malagon","year":"2012","journal-title":"The Lancet Infectious Diseases"},{"key":"10.1016\/j.vaccine.2017.07.086_b0170","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1126\/science.276.5321.2024","article-title":"The role of antibody concentration and avidity in antiviral protection","volume":"276","author":"Bachmann","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.07.086_b0175","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1016\/j.vaccine.2007.03.049","article-title":"Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6\/11\/16\/18 L1 virus-like particle (VLP) vaccine","volume":"25","author":"Olsson","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.07.086_b0180","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00139-12","article-title":"An HPV in vitro neutralization assay that recapitulates the in vivo process of infection provides a sensitive measure of L2 infection-inhibiting antibodies","author":"Day","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.07.086_b0185","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.chom.2010.08.003","article-title":"In vivo mechanisms of vaccine-induced protection against HPV infection","volume":"8","author":"Day","year":"2010","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2017.07.086_b0190","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1016\/j.vaccine.2011.05.041","article-title":"Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults","volume":"29","author":"Turley","year":"2011","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17310125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17310125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T21:28:28Z","timestamp":1602624508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17310125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":38,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0264410X17310125"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.07.086","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.07.086","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}